Rani Therapeutics (RANI) Competitors $0.50 +0.04 (+9.17%) Closing price 04:00 PM EasternExtended Trading$0.49 -0.01 (-2.63%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RANI vs. CLLS, CRDF, FBRX, HURA, CHRS, BHST, IKT, ACOG, ZURA, and CABAShould you be buying Rani Therapeutics stock or one of its competitors? The main competitors of Rani Therapeutics include Cellectis (CLLS), Cardiff Oncology (CRDF), Forte Biosciences (FBRX), TuHURA Biosciences (HURA), Coherus Oncology (CHRS), BioHarvest Sciences (BHST), Inhibikase Therapeutics (IKT), Alpha Cognition (ACOG), Zura Bio (ZURA), and Cabaletta Bio (CABA). These companies are all part of the "pharmaceutical products" industry. Rani Therapeutics vs. Its Competitors Cellectis Cardiff Oncology Forte Biosciences TuHURA Biosciences Coherus Oncology BioHarvest Sciences Inhibikase Therapeutics Alpha Cognition Zura Bio Cabaletta Bio Cellectis (NASDAQ:CLLS) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability. Do analysts prefer CLLS or RANI? Cellectis currently has a consensus target price of $4.00, suggesting a potential upside of 49.25%. Rani Therapeutics has a consensus target price of $7.33, suggesting a potential upside of 1,360.24%. Given Rani Therapeutics' higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than Cellectis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Rani Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings & valuation, CLLS or RANI? Rani Therapeutics has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCellectis$49.22M3.03-$36.76M-$0.82-3.27Rani Therapeutics$1.03M35.04-$30.02M-$0.91-0.55 Is CLLS or RANI more profitable? Rani Therapeutics has a net margin of 0.00% compared to Cellectis' net margin of -100.69%. Cellectis' return on equity of -68.05% beat Rani Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cellectis-100.69% -68.05% -21.53% Rani Therapeutics N/A -1,258.76%-97.97% Do institutionals & insiders hold more shares of CLLS or RANI? 63.9% of Cellectis shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 45.1% of Rani Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media favor CLLS or RANI? In the previous week, Cellectis had 3 more articles in the media than Rani Therapeutics. MarketBeat recorded 4 mentions for Cellectis and 1 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 1.00 beat Cellectis' score of 0.17 indicating that Rani Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Cellectis Neutral Rani Therapeutics Positive Which has more volatility and risk, CLLS or RANI? Cellectis has a beta of 3.03, suggesting that its share price is 203% more volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of -0.02, suggesting that its share price is 102% less volatile than the S&P 500. SummaryRani Therapeutics beats Cellectis on 8 of the 15 factors compared between the two stocks. Get Rani Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RANI vs. The Competition Export to ExcelMetricRani TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.06M$3.15B$5.76B$9.92BDividend YieldN/A2.28%6.67%4.52%P/E Ratio-0.5521.1075.6026.68Price / Sales35.04431.08538.82209.12Price / CashN/A45.1137.1158.92Price / Book8.379.8611.446.09Net Income-$30.02M-$53.47M$3.28B$266.14M7 Day Performance-1.55%2.89%0.84%0.28%1 Month Performance-8.02%8.62%7.15%4.14%1 Year Performance-81.60%13.69%59.66%23.93% Rani Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RANIRani Therapeutics3.107 of 5 stars$0.50+9.2%$7.33+1,360.2%-83.7%$33.06M$1.03M-0.55110Positive NewsShort Interest ↓Gap UpCLLSCellectis2.4394 of 5 stars$2.57-1.2%$4.00+55.6%+14.3%$143.02M$49.22M-3.13290Short Interest ↑CRDFCardiff Oncology2.8196 of 5 stars$2.10+1.0%$10.10+381.0%-2.7%$139.70M$680K-2.4120FBRXForte Biosciences3.5171 of 5 stars$11.00-2.0%$68.00+518.2%+50.1%$136.76MN/A-0.685Options VolumeHigh Trading VolumeHURATuHURA Biosciences1.542 of 5 stars$2.70-3.9%$12.67+369.1%N/A$135.13MN/A0.00N/ACHRSCoherus Oncology4.1965 of 5 stars$1.16-1.7%$4.68+303.7%+0.0%$134.82M$266.96M0.75330News CoverageAnalyst UpgradeGap UpBHSTBioHarvest SciencesN/A$8.18+2.8%$13.67+67.1%N/A$134.36M$25.19M-11.69N/APositive NewsIKTInhibikase Therapeutics1.6575 of 5 stars$1.80-2.2%$6.50+261.1%+26.7%$134.13MN/A-0.676Positive NewsACOGAlpha Cognition2.279 of 5 stars$8.30+3.0%$20.00+141.0%N/A$134.13MN/A-5.19N/APositive NewsZURAZura Bio3.3458 of 5 stars$2.04-3.8%$14.00+586.3%-47.6%$132.64MN/A-2.913News CoverageCABACabaletta Bio2.9808 of 5 stars$1.45-3.3%$14.43+895.1%-69.6%$132.62MN/A-0.5450News CoverageAnalyst Forecast Related Companies and Tools Related Companies CLLS Alternatives CRDF Alternatives FBRX Alternatives HURA Alternatives CHRS Alternatives BHST Alternatives IKT Alternatives ACOG Alternatives ZURA Alternatives CABA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RANI) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rani Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
